Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.

[1]  M. Simoons,et al.  Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). , 1998, Circulation.

[2]  E. Braunwald,et al.  Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. , 1998, Circulation.

[3]  E. Ohman,et al.  Survival benefit of Abciximab administration during early rescue angioplasty: analysis of 387 patients from the GUSTO-III trial , 1998 .

[4]  R. Califf,et al.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .

[5]  David P Miller,et al.  Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade With Percutaneous Coronary Intervention , 1997 .

[6]  F. Werf.  Clinical Trials with Glycoprotein IIb/IIIa Receptor Antagonists in Acute Coronary Syndromes , 1997, Thrombosis and Haemostasis.

[7]  R. Califf,et al.  Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Compl , 1997, Journal of the American College of Cardiology.

[8]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[9]  Stgrp Capture,et al.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.

[10]  Wroe Cd.  Report from the 46th annual scientific session of the American College of Cardiology, Anaheim, California, 16-19 March 1997. , 1997 .

[11]  I. Palacios,et al.  Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. , 1997, Circulation.

[12]  R. Califf,et al.  Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. , 1997, Circulation.

[13]  R. Fox,et al.  Meeting highlights. The 69th Scientific Sessions of the American Heart Association in New Orleans, La, November 10-13, 1996. , 1997, Circulation.

[14]  A. Keech,et al.  Delaying and Preventing Ischemic Events in Patients with Acute Coronary Syndromes Using the Platelet Glycoprotein IIb/IIIa Inhibitor Lamifiban , 1997 .

[15]  A. Keech,et al.  Amplification of clinical benefit at six months with the glycoprotein IIb/IIIa inhibitor lamifiban in patients with non ST segment elevation in acute coronary syndromes , 1997 .

[16]  K. Koch,et al.  Clinically stable angina pectoris is not necessarily associated with histologically stable atherosclerotic plaques. , 1996, Heart.

[17]  P. Théroux,et al.  Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. , 1996, Circulation.

[18]  R. Califf,et al.  Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. , 1996, The American journal of cardiology.

[19]  R. Virmani,et al.  Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. , 1996, Circulation.

[20]  A. Maseri.  Ischemic Heart Disease: A Rational Basis for Clinical Practise and Clinical Research , 1995 .

[21]  V. Fuster,et al.  Coronary plaque disruption. , 1995, Circulation.

[22]  P. Libby.  Molecular bases of the acute coronary syndromes. , 1995, Circulation.

[23]  J. Willerson.  Conversion from chronic to acute coronary heart disease syndromes. Role of platelets and platelet products. , 1995, Texas Heart Institute journal.

[24]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[25]  A. Becker,et al.  Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. , 1994, Circulation.

[26]  R. Califf,et al.  Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. , 1993, Journal of the American College of Cardiology.

[27]  B Meier,et al.  Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. , 1992, The American journal of cardiology.

[28]  E. Falk,et al.  Coronary thrombosis: pathogenesis and clinical manifestations. , 1991, The American journal of cardiology.

[29]  H. Gold,et al.  Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. , 1990, Journal of the American College of Cardiology.

[30]  A. Maseri,et al.  Coronary stenoses before and after acute myocardial infarction. , 1989, The American journal of cardiology.

[31]  A. Maseri,et al.  Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. , 1988, European heart journal.

[32]  W. Santamore,et al.  Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? , 1988, Circulation.

[33]  V. Fuster,et al.  Angiographic progression of coronary artery disease and the development of myocardial infarction. , 1988, Journal of the American College of Cardiology.

[34]  H. Gold,et al.  Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. , 1988, The Journal of clinical investigation.

[35]  H. Gold,et al.  Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. , 1988, Circulation.

[36]  M J Davies,et al.  Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. , 1985, British heart journal.

[37]  M S Golden,et al.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.

[38]  P. Constantinides,et al.  Plaque fissures in human coronary thrombosis , 1966 .